BioExx Forms Science Advisory Board and Announces New VP

    TORONTO, Oct. 10 /CNW/ - Bio-Extraction Inc. (BXI:TSX-V) ("BioExx") is
pleased to announce that effective October 1, 2007, it has formed a new
Science Advisory Board. The purpose of the Science Advisory Board will be to
bring the knowledge and experience of the individual members together to
assist BioExx in fulfilling its mission to become a world leader in cold
temperature extraction technologies and in the production of Protein
Concentrates from oilseed feedstocks.
    Each member brings a vast amount of market and technical knowledge in
their respective fields including engineering and design for low temperature
extraction technology, chemical innovations and diagnostic chemistry, large
scale process and product development, health and nutrition, and aquaculture
nutrition and feed development. Each of these areas of expertise will help
ensure that the first plant being constructed by BioExx will be able to
maximize its effectiveness at producing its multiple products while
maintaining the highest quality and lowest cost per unit of any comparable
    The Advisory Board comprises four highly respected scientists who have
agreed to serve for renewable periods of two years. They are:

    Dr. Peter F. Wilde (B.Sc., Ph.D., F.R.I.C., F.L.S.)

    Dr. Wilde has almost 50 years experience of bringing technical innovation
    from basic concept to the international marketplace. For most of the past
    30 years he has run his own intellectual property based businesses,
    having signed dozens of Patents as "inventor" which has given rise to
    several basic manufacturing businesses. In earlier years, after leaving
    Cambridge, he was Head of the Skin Biochemistry group of Unilever
    Research at Isleworth, UK and then Technical Director of the UK
    subsidiary of American Cyanamid (now SyQuest) responsible for preparing
    polyelectrolytes. In the late 1980s, he invented and pioneered the
    process of extraction of fine oils from plants (initially English Rose
    Oil) using refrigerant-based solvents, for the flavour, fragrance and
    pharmaceutical industries. Dr. Wilde was the inventor of two key Patents
    now owned by BioExx.

    He now offers consultancy services in the fields of fine plant extracts
    to numerous clients in many countries, notably, France and Italy,
    Malaysia, China, India, Pakistan, and Thailand, where he is responsible
    for the design and erection of a large scale extraction plant and
    equipment. International companies such as British Aerospace, Cadbury
    Schweppes, Tate and Lyle, Shell Petroleum Company have used his services.
    He is currently working with OTECI (Medecins Sans Frontieres) on the
    production of the anti-malarial drug Artemisinin.

    He was awarded a B.Sc. (Hons) from Leeds University in microbiology and
    his Ph.D. was obtained at Leeds Medical School, Department of
    Experimental Pathology, where he was Angus Rhodes Cancer Research Fellow.
    He was elected a Fellow of the Royal Institute of Chemistry in 1967 and a
    Fellow of the Linnaean Society of London in 1995.

    Dr. Tom MacMurray (B.Sc., Ph.D.)

    Dr. MacMurray has 40 years experience involved in research chemistry,
    product and process development, and marketing. He spent almost 30 years
    with H.J. Heinz where he joined their UK Research Laboratories in London
    as a research chemist, moved through product and process development and
    eventually became head of Research. He then spent two years as GM,
    Marketing before moving to Heinz World Headquarters in Pittsburgh in 1984
    as director of Research and then Corporate VP, Technical Development. Tom
    coordinated the research and engineering around the world for Heinz and
    has worked in over 20 countries from China and Korea and India to
    Australia, New Zealand, Japan, Zimbabwe, S. Africa and all across North
    America and Western Europe. For his last two years at Heinz, Dr.
    MacMurray was Regional Director, Central and Eastern Europe. He sat on a
    number of industry committees such as International Life Sciences
    Institute, Food Processors Association Regulatory and Scientific Affairs,
    SUSTAIN, and The National Food Labs.

    Dr. MacMurray has also been involved as a consultant and entrepreneur in
    the development of several technologies and businesses including: being a
    joint founder and Executive Vice-President of Country Gourmet Foods, the
    developers and marketers of Wolfgang Puck Soups, Stocks and Broths; an
    early investor and Board member of KCRS Inc., a software company
    specialising in health and productivity management. He was a member of
    the advisory board of Carnegie Mellon Research Institute where he worked
    on specialized radio frequency extraction technology that recovered oil
    from steel sludge; he founded a company to commercialise technology for
    oil extraction using propane and other hydrocarbon mixtures but prefers
    to work with established companies in this field. He is currently
    establishing a startup microwave snack company.

    Dr. MacMurray was born in Glasgow, Scotland and graduated from Glasgow
    University with an honours degree in Agricultural Chemistry and from
    Strathclyde University with a Ph.D. in Food Science.

    Dr. Albert G.J. Tacon (B.Sc., Ph.D.)

    Dr. Tacon has more than 30 years specializing in the aquaculture
    nutrition and feed development industries. He has held numerous
    employment and fellowship positions that most notably include: Member,
    Aquaculture Working Group, National Organic Program (NOP) Aquatic Species
    Task Force (USDA); President, International Aquafeed Association; Editor
    in Chief, Reviews in Aquaculture (Blackwell Publishing); Technical
    Director - Aquaculture Research & Development, Aquatic Farms Ltd, Hawaii,
    USA; Technical Director & Program Manager, The Oceanic Institute, Hawaii,
    USA; FAO Fishery Resources Officer (Feed Specialist), Fisheries
    Department, FAO, Rome, Italy; FAO Feed and Nutrition Adviser, Seafarming
    Development Project, Bandar Lampung, Indonesia; FAO Aquaculture Nutrition
    & Feeding Expert, Support to the Regional Aquaculture Activities of Latin
    America & the Caribbean Project, Pirasanunga/Brasilia, Brazil; FAO Fish
    Feed Technologist, Aquaculture Development and Coordination Programme,
    Rome, Italy.

    Dr. Tacon has 193 publications and one patent on aquaculture technology,
    including publications related to global aquaculture development trends,
    food security and poverty alleviation, aquaculture nutrition and feeding,
    and feed technology. In addition, he is affiliated with several
    Universities and Aquaculture related organizations worldwide.

    Dr. Tacon has a B.Sc. with Honours (Upper Second) in Botany & Zoology
    (specializing in marine zoology) from Westfield College, University of
    London and a Ph.D. from Research, University College (Cardiff),
    University of Wales.

    Dr. Lisette Mascarenhas (M.Sc., Ph.D., MBA)

    Dr. Mascarenhas has almost twenty years of combined training and
    experience in applied research and corporate development of small
    life-sciences companies in Western Canada. Her primary positions have
    included: Vice President: Health and Nutrition, Ag-West Bio Inc. in
    Saskatoon, Saskatchewan; Manager - Diagnostic Applications of Microarrays
    in Organ Transplantation, Genome Alberta in Edmonton, Alberta; and
    Postdoctoral Research Scientist, Agriculture and Agri-Food Canada and
    Department of Anatomy and Cell Biology, University of Saskatchewan in
    Saskatoon, Saskatchewan.

    The combination of a doctorate degree in applied sciences and a Masters
    in Business Administration has allowed her to take on unique
    responsibilities such as the co-management of an investment portfolio of
    start up life science companies; assessing the validity of new
    technologies, market assessment, assessment of intellectual property
    rights protection and freedom to operate (licensing), regulatory
    impediments, environmental reviews and competition assessment. She also
    has experience in managing clinical and non-clinical interactions with
    members of academic, corporate, government, and international life
    sciences and biomedical research communities for the development of large
    co-operative projects. These organizations included the University of
    Alberta, University of Calgary, Roche Molecular Systems, Genome Alberta,
    Alberta Ministry of Innovation and Science among others.

    Dr. Mascarenhas holds a MSc in Applied Microbiology, a PhD in Applied
    Microbiology and a Masters of Business Administration from the University
    of Saskatchewan.

    In their capacity as Science Advisory Board consultants, each of the
individuals has been granted 25,000 stock options, at an exercise price of
$0.30, vesting 1/24 each month, and expiring at the earlier of 24 months from
the grant date or 90 days from the date such individual ceases to be a Science
Advisory Board consultant.

    Appointment of Vice President of Business Development

    BioExx is also pleased to announce that effective October 1, 2007, Samah
Garringer has taken over the role of Vice President of Business Development.
Ms. Garringer joined BioExx in August 2006 as Director of Sales and Marketing
and through the period since has demonstrated a strong aptitude toward all
development aspects of the business including management oversight of R&D
activities, and development of customer and supplier relationships. Ms.
Garringer will take on formal responsibility for all of these areas of the
business to ensure that BioExx succeeds in its mandate to commence
construction of its oilseed extraction facility this year. Ms. Garringer will
also act as facilitator for the Science Advisory Board.
    Ilja Troitschanski who formerly held the title of VP Business Development
will continue to serve the company in a senior consulting capacity on specific
project-related activities.
    "The addition of the Science Advisory Board represents one more important
building block now put in place as we rapidly progress toward constructing our
first full scale facility," says BioExx president, Chris Carl. "Our team has a
strict mandate to conclude development and commence construction of this
facility this year and everyone is working very hard to ensure we succeed at
this. However, this team is also capable of managing the rapid growth that we
foresee that will follow our first plant and I am very excited and proud of
the team that we have established. We are embarking on a commercial path that
promises to set new milestones in the ability to produce foods, fuels, and
industrial products from renewable seed crops. It is our firm intention to
raise the bar significantly in each of these areas."

    About Bio-Extraction Inc.

    BioExx is involved in the development and commercialization of extraction
technology, which it intends to use to extract various active ingredients from
organic and inorganic materials, for its own account and as a service to
industrial customers. Global in scope, the BioExx target markets include
extractions in pharmaceutical, nutraceutical, food oils and fixed oils
(including bio-fuels) and industrial cleansing (eg. specialty steels). Versus
traditional technologies, the patented BioExx technology can offer lower
extraction costs, higher quality extracted materials, and material incremental
revenue opportunities as its extractions can substantially retain the value of
inherent proteins and other sensitive compounds - with all this being
completed in an environmentally responsible manner.
    To find out more about Bio-Extraction Inc. (TSX-V: BXI), please visit our
website at

    The TSX Venture Exchange has not reviewed this press release and neither
    approved nor disapproved the information contained in this press release.

    The statements made in this press release include forward-looking 
statements that involve a number of risks and uncertainties. These statements
relate to future events or future performance and reflect management's current
expectations and assumptions. A number of factors could cause actual events,
performance or results to differ materially from the events, performance and
results discussed in the forward-looking statements, such as the economy,
generally, the demand for BioExx' products, the availability of funding, and
the anticipated costs of BioExx' plant construction and operation. These
forward-looking statements are made as of the date hereof and BioExx does not
assume any obligation to update or revise them to reflect new events or
circumstances. Actual events or results could differ materially from the
BioExx' expectations and projections.

For further information:

For further information: Chris Schnarr, Chief Financial Officer, BioExx,
(416) 588-4442 x.111,; Investor Relations: Scott Koyich,
President, Brisco Capital Partners, (403) 262-9888,;
or On the internet at AGORACOM Investor Relations

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890